Off-label use of tocilizumab to treat non-juvenile idiopathic arthritis in pediatric rheumatic patients: a literature review

Ju-Yang Jung, Moon-Young Kim, Chang-Hee Suh and Hyoun-Ah Kim*

Abstract
Tocilizumab, an anti-interleukin-6 (IL-6) agent, is indicated as a treatment for several autoimmune or inflammatory diseases, including rheumatoid arthritis and juvenile idiopathic arthritis (JIA). IL-6 plays roles in both immune system dysregulation and inflammation, and thus efforts to extend the utility of tocilizumab in patients with autoinflammatory conditions are ongoing. Here, we survey the literature on the off-label use of tocilizumab in patients with juvenile-onset rheumatic diseases including juvenile systemic lupus erythematosus (SLE), juvenile dermatomyositis (DM), vasculitis, juvenile scleroderma, and other autoinflammatory diseases. There is no real evidence that tocilizumab is useful for patients with SLE and juvenile DM, but several cases of childhood Takayasu arteritis have experienced promising outcomes. In juvenile-onset scleroderma, for which no therapy that can halt disease progression is available, tocilizumab may stop progression and the associated functional impairment. Tocilizumab prevents systemic inflammation in patients with Kawasaki’s disease, but may develop coronary aneurysms. Tocilizumab has been used to treat several pediatric autoinflammatory diseases, including JIA-associated uveitis and Castleman’s disease. Further work in larger populations is necessary to confirm the effects of tocilizumab in patients with pediatric rheumatic diseases.

Keywords: Tocilizumab, Interleukin-6, Autoimmune disease, Takayasu’s arteritis

Introduction
Tocilizumab, an anti-interleukin-6 (IL-6) agent, is indicated as a treatment for several autoimmune or inflammatory diseases, including rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA). IL-6 plays roles in both immune system dysregulation and inflammation, and thus efforts to extend the utility of tocilizumab in patients with autoimmune conditions are ongoing. Here, we review IL-6 and tocilizumab, an IL-6 receptor blocker, and survey the literature on off-label tocilizumab use in pediatric patients with rheumatic diseases, such as juvenile-onset systemic lupus erythematosus (SLE), juvenile dermatomyositis (DM), vasculitis, and juvenile scleroderma.

IL-6 and its receptor
IL-6 is produced by many types of cells including those of the immune system. It is barely detectable in healthy subjects, but its levels increase after infection or tissue damage [1]. IL-6 is released from macrophages, neutrophils, dendritic cells, and cluster of differentiation 4 (CD4) T cells, and it is associated with the clinical symptoms and signs of inflammation (such as fever and/or fatigue). IL-6 may induce bone marrow leukocytosis and thrombocytosis, stimulate hepatocytes to release C-reactive protein (CRP) and acute-phase markers affecting the erythrocyte sedimentation rate (ESR), activate neutrophils and macrophages, and cause T-helper cells to differentiate into type 17 T-helper (Th17) cells [2]. On the other hand, it inhibits T-regulatory (Treg) cells, and the resulting Th17/Treg imbalance compromises immunological tolerance [3]. It also promotes the differentiation of B cells into antibody-producing cells and CD8-positive T cells into cytotoxic T cells [1, 4, 5]. It acts via a ubiquitous receptor (IL-6R) composed of two chains, IL-6R and gp130; the latter transduces the IL-6 signal into cells [6–8]. IL-6R expression is restricted to certain cells including leukocytes and hepatocytes, but
gp130 is expressed in almost all cells [9]. A soluble form of IL-6R is found in human serum, and an IL-6/soluble IL-6R complex can bind to cells lacking IL-6R, transducing the IL-6 signal via gp130 without any need for transmembrane IL-6R [10]. The IL-6 signal activates "signal transducer and activator of transcription 3," triggering the secretion of many proteins including CRP and haptoglobin, which mount inflammatory reactions. IL-6 plays a critical role in terms of coordination of the innate and adaptive immune responses and the switch from acute to chronic inflammation, and is considered a useful target in a variety of autoimmune diseases.

Tocilizumab
Tocilizumab, a humanized anti-IL-6R monoclonal antibody, is the first drug to be found to successfully block the IL-6 signal; the drug binds to both cell-surface and soluble IL-6R [11]. Tocilizumab was designed by a group led by Tadamitsu Kishimoto, and was approved by the U.S. Food and Drug Administration (FDA) in 2010 for the treatment of RA. It alleviates inflammation and prevents bone damage associated with RA, moderating disease activity (including joint tenderness and swelling) and disease activity scores within 1 month after commencement [12]. Furthermore, the FDA approved the drug as a treatment for systemic JIA in 2011, for polyarticular JIA in 2013, and for giant cell arteritis in 2017. Tocilizumab effectively treats refractory adult-onset Still's disease, the adult form of systemic JIA, polymyalgia rheumatica, and various manifestations of giant cell arteritis via its steroid-sparing effects [13–15]. Efforts to explore and extend the utility of tocilizumab are ongoing; off-label tests in patients with other systemic inflammatory diseases are underway.

Methods
We screened PubMed and MEDLINE using the terms “tocilizumab” AND “pediatric” OR “autoinflammatory”, and “juvenile”. Among the 466 retrieved articles published between November 1994 and August 2018, 256 articles reporting on the use of tocilizumab in patients with JIA were excluded. Randomized and nonrandomized controlled trials, case-control studies, cohort studies, and case series and single case reports involving pediatric patients treated with tocilizumab were included. The remaining 210 articles were reviewed, of which 71 articles described pediatric diseases treated with tocilizumab in patients not diagnosed with JIA.

Information related to tocilizumab treatment, including patient age at the time of diagnosis, sex, age at the time of tocilizumab therapy, disease duration before tocilizumab therapy, tocilizumab dose and administration route, previous use of immunosuppressive agents, doses of glucocorticoids before and after tocilizumab treatment, concurrent treatments, response to tocilizumab therapy, and adverse events related to tocilizumab infusion, was collected.

Results
SLE
SLE is a systemic autoimmune disease involving the skin, joints, kidneys, and other organs via autoantibody production and the formation of immune complexes. Childhood-onset SLE is rare (0.3–0.9/100,000 subjects); the median age at onset is about 11 years [16]. Pediatric SLE exhibits a more severe course than adult SLE and is associated with a higher rate of morbidity [17]. Serum IL-6 levels are elevated and correlated with disease activity in patients with lupus [18]. IL-6 administration to lupus-prone mice increases autoantibody production and accelerates the progression of glomerulonephritis [19]. In an open-label phase I study, tocilizumab improved the disease scores of patients with moderately active SLE, but neutropenia and infection developed in a dose-dependent manner [20]. Nonetheless, several case reports have described the successful use of tocilizumab in the treatment of SLE flares in adult patients [21–23]. Combined cyclophosphamide and tocilizumab treatment improved massive pericarditis and glomerulonephritis in a patient with refractory SLE [24]. However, the use of tocilizumab to treat pediatric patients with SLE has not been well examined. In a previous case report, we described the results of tocilizumab therapy in a 20-year-old patient with SLE (diagnosed at the age of 13 years). Prior to therapy, she experienced recurrent flare-ups, with fever, lymphadenopathy, and erosive inflammatory arthritis; she was negative for rheumatoid factor and anti-citrullinated protein antibody. After tocilizumab was commenced, her arthritis and inflammatory markers resolved and her glucocorticoid dose was successfully reduced [25].

Juvenile DM
Juvenile DM is the most common form of myositis in children, characterized by symmetrical, proximal muscle weakness with typical rashes (Gottron’s papules and the heliotrope rash) [26, 27]. The rashes reflect an immune system-mediated vasculopathy involving the periungual capillaries. The median age at onset is 7.5 years, and 24–40% of patients recover within 2 years. Serum levels of IL-6 increase in patients with either adult or juvenile DM, and are associated with disease activity [28–30]. A case report described an adult patient with concomitant DM, SSc, and RA whose disease activity improved with tocilizumab therapy [31]. In one case, a 12-year-old patient with juvenile DM, treated with glucocorticoids and methotrexate (MTX), relapsed with Raynaud’s phenomenon, sclerodactyly, and polyarthritis [32]. After several drugs failed, tocilizumab was initiated, but improved joint manifestations only.
Vasculitis
Takayasu arteritis (TA) is a granulomatous vasculitis involving the aorta and its main branches, and occurs in both adult and children [33]. TA manifests as constitutional symptoms such as weight loss and anorexia, and progresses to claudication and hypertension caused by pathological vascular narrowing or occlusion. Glucocorticoids are the mainstay of therapy; immunosuppressive agents including MTX and cyclophosphamide play roles as glucocorticoid-sparing agents [34]. In TA patients, IL-6 is synthesized by activated dendritic cells in the walls of blood vessels, activating CD4+ T cells and induces the maturation of Th1 and Th17 cells [35]. IL-6 levels are elevated in serum and aortic tissue. Several studies have found that tocilizumab is effective for adults with TA [36, 37]. Table 1 lists the results of tocilizumab treatment in patients with childhood TA. In one study, a 3-year-old girl with fever, a cardiac murmur, and absence of the right radial pulse was diagnosed with TA because of a high level of CRP, thickening of the aortic-arch wall, and complete occlusion of the common carotid arteries [38]. High-dose prednisone and MTX suppressed the disease, but the condition was repeatedly reactivated when the glucocorticoid was tapered. Etanercept and infliximab were ineffective; then she received several immunosuppressive agents and achieved partial disease control that was glucocorticoid-dependent. Tocilizumab was commenced when she developed a new relapse associated with elevated inflammatory marker levels and retrosternal pain. Disease activity was reduced and the prednisone dose was lowered after 15 months. Four pediatric TA cases treated with tocilizumab have been reported; the clinical and laboratory responses were good [39]. In that study, all patients with active disease achieved an inactive state (no new vascular lesion) after 3 months of tocilizumab injections. In another case, a 13-year-old girl with fever, weight loss, mesenteric claudication, and left shoulder pain was diagnosed with TA based on fluorodeoxyglucose uptake (evident via positron emission tomography–computed tomography [PET-CT]) by the aortic arch of the descending aorta, the left internal carotid artery, and the left subclavian artery [40]. High-dose corticosteroids with MTX were initially effective, but the disease relapsed. Infliximab therapy failed and tocilizumab was commenced at 8 mg/kg monthly. The symptoms and inflammatory marker levels were improved and PET-CT revealed no FDG uptake after 3 months of therapy. Several other cases in which pediatric patients with TA were treated successfully with tocilizumab have been reported [41, 42]. Two pediatric patients with in-stent restenosis had stable disease activity during tocilizumab therapy, although disease reactivation occurred in one patient 3 months after tocilizumab withdrawal [42].

Scleroderma
Systemic sclerosis (SS, also termed scleroderma) is a systemic autoimmune disease characterized by autoantibody production, inflammation of skin and soft tissue, and fibrosis. Juvenile scleroderma includes juvenile localized scleroderma and juvenile systemic scleroderma [43]. Most current drugs including MTX are ineffective against both juvenile and adult scleroderma. The peripheral B cells of adults with SS secrete IL-6, the serum levels of which correlate with disease activity and the extent of internal organ involvement [44, 45]. In a phase 2, randomized controlled trial on adults with SS, tocilizumab failed to improve skin thickening significantly but slowed the decline in forced vital capacity [46]. Two children with pansclerotic morphea (a severe subtype of

Table 1 Off-label use of tocilizumab (TCZ) in pediatric patients with Takayasu arteritis

| Authors, year (ref.) | Sex | Age at onset, years | Age at TCZ, years | Manifestations | Previous therapy | Dose of TCZ, months | Duration of TCZ, weeks | Adverse effect of TCZ |
|----------------------|-----|---------------------|------------------|---------------|------------------|---------------------|------------------------|----------------------|
| Bravo Mancheno et al., 2012 [38] | F 3 | 5 | Wall thickening, occlusion | GC, MTX, ETN, IFX, CYC, MMF | 8 mg/kg /2-3 weeks | > 24 | No |
| Batu et al., 2017 [39] | F 4 | 9 | Stenosis | GC, CYC, MTX, AZA | 8 mg/kg /4 weeks | 7–13 | No |
| F 14 | 15 | Aneurysms | GC, CYC, MTX, AZA | 8 mg/kg /4 weeks | 7–13 | No |
| F 16 | 16 | Aneurysms | GC, CYC, MTX, ETN | 8 mg/kg /4 weeks | 7–13 | No |
| F 16 | 16 | Wall thickening | GC | 8 mg/kg /4 weeks | 18 | No |
| Decker et al., 2018 [40] | F 13 | 15 | Panaortitis | GC, MTX, IFX | 8 mg/kg /4 weeks | 18 | No |
| Canas et al., 2014 [41] | F 12 | 13 | Wall thickening | GC | 8 mg/kg /4 weeks | 18 | No |
| F 14 | 13 | Wall thickening | GC, MTX | 8 mg/kg /4 weeks | 18 | No |
| Goel et al., 2013 [42] | F 13 | 13 | In-stent restenosis | GC, MMF | 8 mg/kg /4 weeks | 6 | No serious AE |
| F 14 | 15 | In-stent restenosis | GC, MMF | 8 mg/kg /4 weeks | 6 | No serious AE |

GC glucocorticoids, MTX methotrexate, ETN etanercept, IFX infliximab, CYC cyclophosphamide, MMF mycophenolate mofetil, AZA azathioprine
localized scleroderma) refractory to various immunosuppressive agents were treated with tocilizumab [47]; disease activity was controlled and progression ceased. Five patients aged 6–13 years with localized scleroderma refractory to immunosuppressants (including MTX and mycophenolate mofetil) or etanercept were started on tocilizumab [48]. Disease activity, tissue damage, and quality-of-life improved after 3 months; all patients tolerated tocilizumab for 12–25 months without any serious adverse reactions. No drug of choice is yet available for juvenile scleroderma; tocilizumab may control inflammation and stop progression.

**Autoimmune encephalitis**

Autoimmune encephalitis (AE) is an inflammatory disorder of the central nervous system [49, 50]. It commonly presents with the sudden onset of memory deficit, altered mental status, psychiatric symptoms and seizure, cerebrospinal fluid pleocytosis, and magnetic resonance imaging features of encephalitis. Although the discovery of pathogenic autoantibodies has changed the diagnosis and treatment of AE, diagnostic and therapeutic challenges remain. Immunosuppressive therapy, including high-dose glucocorticoids and cyclophosphamide, is used to minimize permanent neurological damage. Thirty adult patients with inadequate clinical responses to rituximab therapy received tocilizumab, which resulted in favorable clinical responses in all cases [51]. A case series described two pediatric patients with seizure and one with ataxia and cognitive dysfunction with disease refractory to glucocorticoids and cyclophosphamide, and rituximab [52]. Following deterioration of their neurological symptoms, they were treated with tocilizumab, which resulted in symptom resolution after 2 to 4 weeks. The successful use of tocilizumab supports its administration to pediatric patients with refractory and aggressive autoimmune encephalitis.

**Kawasaki’s disease**

Kawasaki’s disease is an acute, self-limiting vasculitis affecting the medium-sized blood vessels of infants and children [53, 54]. Although high-dose, intravenous immunoglobulin (IVIG) treatment is effective, 25% of children develop coronary artery aneurysms. A cytokine storm including tumor necrosis factor (TNF)-α, IL-6, and granulocyte colony-stimulating factor is evident in patients in whom coronary artery aneurysms are developing [55]. Four patients, two 1-year-old girls and 8- and 4-year-old boys with IVIG-resistant Kawasaki’s disease, were treated with tocilizumab [56]. All recovered from fever and leukocytosis, and inflammatory marker levels fell, but the two girls developed progressive giant coronary artery aneurysms. IL-6 plays a role in tissue regeneration; tocilizumab may disrupt this process by blocking the action of vascular endothelial growth factor. These cases suggest that tocilizumab may trigger new-onset coronary aneurysms.

**JIA-associated refractory uveitis**

Tocilizumab effectively treats not only systemic or polyarticular JIA, but also JIA-associated uveitis [57–60], which presents as chronic nongranulomatous anterior uveal inflammation causing permanent ocular damage and visual loss. Several case reports and multicenter studies have reported that tocilizumab is valuable in patients with JIA-associated refractory uveitis (Table 2) [58, 59, 61, 62]. One study used tocilizumab to treat JIA-associated uveitis refractory to immunosuppressive drugs and anti-TNF agents [58]. Overall, 79.2% of patients exhibited improvements in anterior chamber cell numbers; steroid-sparing was possible. However, serious complications including severe autoimmune thrombocytopenia and pneumonia have been reported. A recent study described four patients with long-term, JIA-associated chronic anterior uveitis who exhibited good sustained responses on intravenous tocilizumab [63]. However, they experienced early flares after switching to subcutaneous tocilizumab. Ocular disease was more readily controlled by intravenous rather than subcutaneous tocilizumab.

**Castleman’s disease**

Increased IL-6 levels have been observed in Castleman’s disease, which is a poorly understood lymphoproliferative disorder driven by proinflammatory hypercytokinaemia [64]. One study found that tocilizumab was efficacious in two children with multicentric Castleman’s disease who developed sustained fever after treatment with an IL-1 agonist or IVIG [65]. A 21-month-old boy with multicentric Castleman’s disease responded incompletely to initial tocilizumab treatment, but improved after subsequent chemotherapy [66]. In another case, a 16-year-old male was diagnosed with multicentric Castleman’s disease associated with abdominal pain, fatigue, weakness, fever, and night sweats [67]. He exhibited sustained remission after multi-agent chemotherapy and maintenance tocilizumab therapy, which suggests that tocilizumab is useful for treating multicentric Castleman’s disease.

**Amyloid a amyloidosis**

Secondary amyloidosis may develop in patients with chronic inflammatory diseases, including JIA, invading the kidneys, liver, heart, gastrointestinal system, and autonomic nervous system [68]. Tocilizumab therapy was reported to improve renal amyloidosis-related systemic-onset JIA in three female patients aged 26, 29, and 19 years [69, 70]. These three patients had been...
Table 2 Off-label use of tocilizumab in pediatric patients with JIA-associated uveitis

| Authors, year | Sex  | Age at onset, years | Age at TCZ, years | Previous therapy | Dose of TCZ | Efficacy of TCZ | Duration of TCZ | Adverse effect of TCZ |
|---------------|------|---------------------|-------------------|-----------------|-------------|----------------|-----------------|---------------------|
| Tsang et al., 2014 [60] | M 3 | 12 | GC, MTX, ADA, RTX | 8 mg/kg/2–4 weeks | Quiescence of uveitis | 20 weeks | Neutropenia when infused every 2 weeks |
| Tappeiner et al., 2016 [58] | F & M | 14.3 | 15.3 ± 6.9 | GC, MTX, ≥1 TNF-α inhibitor | Inactive in 10, persisted in 7 | 5.7 months | No |
| Calvo-Rio et al., 2017 [57] | F & M | 21.4 | 18.5 ± 8.3 (8–38) | GC, MTX, IFX, ETN, ADA, GLM, ABA, ANK, RTX | 8 mg/kg/2, 4, 8 weeks | Inactive in 19 cases | 5.5–24 months | Thrombocytopenia (1), pneumonia, thrombocytopenia, and hemolytic anemia (1), Viral conjunctivitis and bullous impetigo (1) |
| Quesada-Masachs et al., 2017 [62] | F | 1.9 | 14 | MTX, leflunomide, ADA | 8 mg/kg/month switching to 162 mg/week SC | Ocular flare after 6 months | 6 months | No |

TCZ: tocilizumab, GC: glucocorticoids, MTX: methotrexate, ADA: adalimumab, RTX: rituximab, TNF: tumor necrosis factor, IFX: infliximab, ETN: etanercept, GLM: golimumab, ABA: abatacept, ANK: anakinra

diagnosed with systemic JIA, at 14, 6, and 9 years of age, respectively, and they were treated with MTX, cyclophosphamide, or etanercept with glucocorticoids before the diagnosis of amyloidosis. One of the patients, with gastrointestinal and renal involvement, had improved levels of inflammatory markers and symptom reduction after tocilizumab infusion. In another patient, amyloidosis developed during a treatment regimen of 8 mg tocilizumab/kg every 4 weeks; the tocilizumab dose was thus increased to 8 mg/kg every 2 weeks. Clinical improvement occurred within 3 months.

Cytokine release syndrome

Cytokine release syndrome (CRS) is a serious response of patients with hematological malignancies to novel T cell-engaging therapies [71, 72]. High-level immune activation, including T cell activation and cytokine level elevation, results in fever and other manifestations, including cardiac dysfunction, toxicity, renal or hepatic failure, and disseminated intravascular coagulation. Tocilizumab was used to control severe symptoms in two pediatric patients with relapsed acute lymphoblastic leukemia (ALL) who developed CRS after chimeric antigen receptor-modified T cell therapy [73]. The 7-year-old male and 11-year-old female were each treated with a single dose of 8 mg tocilizumab/kg, and both patients had clinical responses that included improved hemodynamic status, blood cell counts, and inflammatory markers. Tocilizumab is recommended for patients with grade 3 and 4 CRS, with life-threatening symptoms requiring aggressive intervention. In a phase I/IIa clinical trial of chimeric antigen receptor-modified T cell therapy for relapsed/refractory ALL, 13 of 39 patients with CRS had cardiovascular dysfunction and were thus treated with tocilizumab. Four patients received more than one dose of tocilizumab, but all patients recovered from the CRS [74].

Other autoinflammatory conditions

Systemic autoinflammatory disorders are closely associated with gene mutations and are caused by the dysregulation of innate immunity. TNF receptor-associated periodic syndrome (TRAPS) is an autosomal dominant inherited autoinflammatory disorder caused by mutations in the gene encoding the TNF receptor. It is characterized by recurrent and prolonged fever, myalgia, arthralgia, erysipelas, and serositis. A 4-year-old boy diagnosed with TRAPS related to a heterozygous variant in the TNFRSF1A gene had already received glucocorticoids, anti-IL-1β monoclonal antibody, TNF inhibitor (infliximab), and tocilizumab based on a previous diagnosis of systemic JIA [75]. After the DNA mutation was identified, he received a tocilizumab infusion, which resulted in the sustained remission of all symptoms for at least 2 years.

H syndrome, also called pigmentary hypertrichosis and non-autoimmune insulin-dependent diabetes mellitus (PHID) syndrome, is an autosomal recessive genetic disorder whose features include the childhood onset of skin lesions associated with autoantibody-negative insulin-dependent diabetes mellitus [76]. The condition, caused by a mutation in SLC29A3, is characterized by severe autoinflammation and the increased production of pro-inflammatory cytokines. Four patients with PHID whose disease manifestations had emerged at the age of 2–5 years were treated with tocilizumab [77, 78]. In the three patients who received a TNF inhibitor after MTX or cyclosporin, the symptoms continued. Tocilizumab therapy, as an intravenous infusion administered at a dose of 8 mg/kg or injected subcutaneously at a dose of 10.8–12 mg/kg every 2 weeks, was started when the patients reached the ages of 3–19 years, to treat the severe ongoing systemic inflammation.

A 15-year-old girl presented with exertional dyspnea, hemoptysis, episodic fever, oropharyngeal ulcer, arthritis, and vasculitic rash. Based on the clinical work-up,
including lung biopsy, she was diagnosed with an undifferentiated autoinflammatory disease with interstitial pneumonitis [79]. Infusions of IL-1 receptor antagonist improved the rash, oral ulcer, and arthritis, but aggravated the patient’s respiratory symptoms. After tocilizumab therapy, amelioration of her extrapulmonary symptoms, oxygen saturation, and flares of dyspnea was achieved, accompanied by a decrease in parenchymal ground-glass changes, as determined by computed tomography.

**Grave’s disease**

Grave’s ophthalmopathy occurs mainly in Grave’s hyperthyroidism, which is caused by thyroid-stimulating hormone receptor-stimulating antibodies produced by lymphocytes in the thyroid gland or lymph nodes [80]. It initially involves the extraocular muscles, but then expands to the orbital fat and subcutaneous tissue, leading to swelling and redness of the eyelids and conjunctiva, exophthalmos, and double vision. Disease refractory to systemic glucocorticoids and surgical orbital decompression results in corneal ulceration and the loss of visual acuity. Immunosuppressants have been prescribed in severe cases, given the inflammatory pathogenesis of thyroid eye disease. Orbital fibroblasts produce excessive IL-6, which recruits and activates T cells to induce the synthesis of hydrophilic glycosaminoglycans, with effects on other immune cells. The improvement of several adult cases of severe thyroid eye disease following tocilizumab therapy has been reported [81, 82]. Moreover, a randomized clinical trial demonstrated the meaningful efficacy of

| Disease                                      | n  | Age, years | Efficacy of TCZ                                      | Dose of TCZ              | Adverse effect of TCZ | References          |
|----------------------------------------------|----|------------|-----------------------------------------------------|--------------------------|-----------------------|---------------------|
| Juvenile SLE                                  | 1  | 13         | Improved arthritis and inflammatory markers         | 400 mg/month             | No                    | [21]                |
| Juvenile dermatomyositis                      | 1  | 12         | Improved arthritis                                  | 8 mg/kg/4 weeks          | No                    | [28]                |
| Takayasu arteritis                            | 12 | 3–16       | Improved symptoms and inflammatory marker           | 8 mg/kg/3–4 weeks        | No                    | [34–38]             |
| Juvenile localized scleroderma                | 7  | 6–13       | Improved disease activity and inhibition of progression | ≥30 kg: 8 mg/kg < 30 kg: 12 mg/kg every 4 weeks | No                    | [47, 48]            |
| Autoimmune encephalitis                      | 3  | 10, 12, 15 | Improved neurological symptoms without recurrence   | 8–12 mg/kg/4 weeks       | No                    | [51]                |
| Kawasaki’s disease                            | 4  | 1–8        | Improved symptoms and inflammatory markers          | 8 mg/kg once             | Giant coronary artery aneurysm (2) | [55]                |
| JIA-associated uveitis                        | 8–38 |           | Improved visual acuity Reduction of GC dose         | 8 mg/kg/4 weeks          | Thrombocytopenia (1), pneumonia, thrombocytopenia, and hemolytic anemia (1), viral conjunctivitis and bullous impetigo (1) | [57, 58, 60, 62] |
| Multicentric Castleman’s disease              | 4  | 1–16       | Sustained remission                                 | 8 mg/kg/2 weeks 10 mg/kg three times 8 mg/kg/2 weeks | Herpes zoster (1) | [64–66]             |
| Amyloid A amyloidosis                         | 3  | 19, 20, 29 | Improved symptoms and inflammatory markers          | 8 mg/kg/2–4 weeks        | No                    | [68, 69]            |
| Cytokine release syndrome (CRS)               | 15 | 7–16       | Improved symptoms and inflammatory markers          | 8 mg/kg 1–3 times        | No                    | [72, 73]            |
| Tumor necrosis factor receptor-associated periodic syndrome (TRAPS) | 1  | 4          | Improved symptoms and inflammatory markers          | 8 mg/kg/month            | No                    | [74]                |
| H syndrome (PHID)                             | 4  | 3–19       | Improved symptoms and inflammatory markers          | IV: 8 mg/kg SQ: 10.8–12 mg/kg every 2 weeks | No                    | [76, 77]            |
| Undifferentiated autoinflammatory disease with interstitial pneumonitis | 1  | 15         | Improved symptoms and reduction of ground-glass opacity on CT | 8 mg/kg/month            | No                    | [78]                |

**Table 3** Off-label use of tocilizumab in pediatric patients with non-JIA rheumatic diseases except Takayasu arteritis and JIA-associated uveitis

*JIA juvenile idiopathic arthritis, SLE systemic lupus erythematosus, TCZ tocilizumab, GC glucocorticoids, IV intravenous, SQ subcutaneous, CT computed tomography*
tocilizumab in 32 patients with moderate to severe corticosteroid-resistant Graves’ ophthalmopathy [83]. Although the use of tocilizumab in pediatric patients with Grave’s ophthalmopathy has not been reported, these results suggest that pediatric Grave’s ophthalmopathy will be responsive to tocilizumab.

Conclusion
IL-6 is a key driver of systemic autoimmune diseases; tocilizumab-mediated IL-6 blockade is effective for children with systemic or polyarticular JIA. Table 3 summarizes the effects of tocilizumab on pediatric rheumatic diseases other than JIA. Little evidence of any therapeutic effects of tocilizumab in patients with SLE and juvenile DM is available, but several cases of childhood TA have exhibited promising responses to treatment. No effective therapy for juvenile scleroderma is available; tocilizumab may stop progression and functional impairment. Tocilizumab is active against systemic inflammation in patients with Kawasaki’s disease, but coronary aneurysms may nonetheless develop. This drug might prevent the loss of visual acuity in patients with JIA-associated uveitis and allow sustained clinical remission in patients with multicentric Castleman’s disease. The use of tocilizumab should be based on consideration of the actual benefits of the drug, in view of possible adverse events, including serious infection.

This literature review supports the use of tocilizumab therapy as one option in the treatment of several pediatric rheumatic diseases, not limited to JIA. Although the role of tocilizumab in the treatment of systemic autoimmune diseases may be insufficient, IL-6 is a protagonist of the inflammasome-mediated autoinflammatory response. Considering the mechanism of IL-6 and the effects of tocilizumab, the drug can be used in several disorders in which autoinflammatory reactions are the main pathogenesis. However, further studies, including well-designed clinical trials, are needed to confirm the effects of tocilizumab and to evaluate its safety profile in larger populations of pediatric patients with rheumatic diseases.

Abbreviations
ALL: Acute lymphoblastic leukemia; CD4: Cluster of differentiation 4; CRP: C-reactive protein; CRS: Cytokine release syndrome; DM: Dermatomyositis; ESR: Erythrocyte sedimentation rate; FDA: Food and Drug Administration; IL-6: Interleukin-6; IVIG: Intravenous immunoglobulin; JIA: Juvenile idiopathic arthritis; MTX: Methotrexate; PET-CT: Positron emission tomography; PHID: Pigmentary hypertrichosis and non-autoimmune insulin-dependent diabetes mellitus; RA: Rheumatoid arthritis; SLE: Systemic lupus erythematosus; SS: Systemic sclerosis; TA: Takayasu arteritis; Treg: T-regulatory receptor-associated pediatric syndrome; TGF-β: Transforming growth factor-β; TRAPS: TNF receptor-associated periodic syndrome; ”Treg” regulatory

Acknowledgements
None

Funding
This research was supported by a grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (grant no. H116C09992).

Availability of data and materials
All data generated or analyzed during this study are included in this article.

Authors’ contributions
JYJ: data collection and analysis, manuscript writing, and final approval of the manuscript. MYK and CHS: data collection and analysis, manuscript writing, and final approval of the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate
Not applicable

Consent for publication
Not applicable

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 4 October 2018 Accepted: 4 December 2018
Published online: 14 December 2018

References
1. Rincon M. Interleukin-6: from an inflammatory marker to a target for inflammatory diseases. Trends Immunol. 2012;33:571–7.
2. Weyand CM, Fulbright JW, Hunder GG, et al. Treatment of giant cell arteritis: interleukin-6 as a biologic marker of disease activity. Arthritis Rheum. 2000;43:1041–8.
3. Kimura A, Kishimoto T. IL-6 regulator of Treg/Th17 balance. Eur J Immunol. 2010;40:1830–5.
4. Galabrese LH, Rose-John S. IL-6 biology: implications for clinical targeting in rheumatic disease. Nat Rev Rheumatol. 2014;10:720–7.
5. Okada M, Kitahara M, Kishimoto S, et al. IL-6/BF-2 functions as a killer helper factor in the in vitro induction of cytotoxic T cells. J Immunol. 1988;141:1543–9.
6. Hibi M, Murakami M, Saito M, et al. Molecular cloning and expression of an IL-6 signal transducer, gp130. Cell. 1990;63:1149–57.
7. Kishimoto T, Akira S, Narazaki M, et al. Interleukin-6 family of cytokines and gp130. Blood. 1995;86:1243–54.
8. Taga T, Hibi M, Hirata Y, et al. Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130. Cell. 1989;58:1243–79.
9. Kishimoto T, Akira S, Taga T. Interleukin-6 and its receptor: a paradigm for cytokines. Science. 1990;250:9–7.
10. Narazaki M, Yasukawa K, Saito T, et al. Soluble forms of the interleukin-6 signal-transducing receptor component gp130 in human serum possessing a potential to inhibit signals through membrane-anchored gp130. Blood. 1993;82:6120–6.
11. Oldfield V, Dhillon S, Plosker GL. Tocilizumab: a review of its use in the management of rheumatoid arthritis. Drugs. 2009;69:609–32.
12. Narkaz M, Kishimoto T. Anti-interleukin-6 receptor antibody, tocilizumab, for the treatment of autoimmune diseases. FEBS Lett. 2011;585:3699–709.
13. Lynch L, Forbes L, Hatzis C, et al. Brief report: a prospective open-label phase IIa trial of tocilizumab in the treatment of polymyalgia Rheumatica. Arthritis Rheumatol. 2016;68:2550–4.
14. Puech X, Delalande M, Berthelot JM, et al. Tocilizumab in refractory adult Still’s disease. Arthritis Care Res (Hoboken). 2011;63:155–9.
15. de Boysson H, Fevrier J, Nicolle A, et al. Tocilizumab in the treatment of the adult-onset Still’s disease: current clinical evidence. Clin Rheumatol. 2013;32:141–7.

16. Kamphuis S, Silverman ED. Prevalence and burden of pediatric-onset systemic lupus erythematosus. Nat Rev Rheumatol. 2010;6:58–66.

17. Baqi N, Moxaim S, Singh A, et al. Lupus nephritis in children: a longitudinal study of prognostic factors and therapy. J Am Soc Nephrol. 1996;7:924–9.

18. Arkan-Israfil M, Deans RJ, Wallace DJ, et al. Elevated levels of endogenous IL-6 in systemic lupus erythematosus. A putative role in pathogenesis. J Immunol. 1991;147:117–23.

19. Ivanov M, Dohi K, Hirata E, et al. Urinary levels of IL-6 in patients with active lupus nephritis. Clin Nephrol. 1993;40:16–21.

20. Illei GG, Shirori Y, Yarboch J, et al. Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum. 2010;62:542–52.

21. Maeshima K, Ishii K, Torigoe M, et al. Successful tocilizumab and tacrolimus treatment in a patient with rheumatoid arthritis complicated by systemic lupus erythematosus. Lupus. 2012;21:1003–6.

22. Garcia-Hernandez FJ, Gonzalez-Leon R, Castillo-Palma MJ, et al. Tocilizumab for treating refractory haemolytic anaemia in a patient with systemic lupus erythematosus. Rheumatology (Oxford). 2012;51:1918–9.

23. Makol A, Gibson LE, Michet CJ. Successful use of interleukin-6 antagonist tocilizumab in a patient with refractory cutaneous lupus and urticarial vasculitis. J Clin Rheumatol. 2012;18:92–5.

24. Iwai A, Naniwa T, Tamechika S, et al. Short-term add-on tocilizumab and intravenous cyclophosphamide exhibited a remission-inducing effect in a patient with systemic lupus erythematosus with refractory multiorgan involvement including massive periarteritis and glomerulonephritis. Mod Rheumatol. 2017;27:529–32.

25. Kim MY, Park S, Suh CH, et al. Patient with systemic lupus erythematosus combined with erosive arthritis was treated successfully with tocilizumab: a case report. J Rheum Dis. 2018;25:144–7.

26. Feldman BM, Rider LG, Reed AM, et al. Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood. Lancet. 2008;371:2201–12.

27. Robinson AB, Reed AM. Clinical features, pathogenesis and treatment of juvenile and adult dermatomyositis. Nat Rev Rheumatol. 2011;7:664–75.

28. Gono T, Kaneko H, Kawaguchi Y, et al. Cytokine profiles in polymyositis and dermatomyositis complicated by rapidly progressive or chronic interstitial lung disease. Rheumatology (Oxford). 2014;53:2196–203.

29. Wakiguchi H, Hasegawa S, Hirano R, et al. Successful control of juvenile dermatomyositis-associated macrophage activation syndrome and interstitial pneumonia: distinct kinetics of interleukin-6 and -18 levels. Pediatr Rheumatol Online J. 2015;13:344–46.

30. Graus F, Titaev M, Balu R, et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol. 2016;15:391–404.

31. Linker-Israeli M, Deans RJ, Wallace DJ, et al. Elevated levels of endogenous interleukin-6 and transforming growth factor beta and Activate fibroblasts. Arthritis Rheumatol. 2017;69:1078–89.

32. Abdel-Magied RA, Kamel SR, Said AF, et al. Serum interleukin-6 in systemic sclerosis and its correlation with disease parameters and cardiopulmonary involvement. Sarcoidosis Vasc Diffuse Lung Dis. 2016;33:321–30.

33. Khanna D, Denton CP, Jahreis A, et al. Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faScinate): a phase 2, randomised, controlled trial. Lancet. 2016;387:2630–40.

34. Martini G, Campus S, Ruffeiner B, et al. Tocilizumab in two children with panarteritis nodosa: a therapeutic option for children with severe, refractory juvenile localized scleroderma. Rheumatology (Oxford). 2018;57:398–401.

35. Welsh RC, Gorman NP, Lim M. Autoimmune encephalitis in children: clinical phenomenology, therapeutics, and emerging challenges. Curr Opin Neurol. 2017;30:334–44.

36. Fujimaru T, Ito S, Morita H, et al. Decreased levels of inflammatory cytokines in immunoglobulin-resistant Kawasaki disease after plasma exchange. Cytokine. 2014;70:156–60.

37. Goel R, Danda D, Kumar S, et al. Rapid control of disease activity by tocilizumab in 10 ‘difficult-to-treat’ cases of Takayasu arteritis. Int J Rheum Dis. 2017;10(Suppl 106):211–3.

38. Lopalco G, Fabiani C, Sota J, et al. IL-6 blockade in the management of non-erosive rheumatoid arthritis: a multicenter study of refractory rheumatoid arthritis patients. PLoS ONE. 2018;13:e0199668.

39. Zulian F, Cuffaro G, Sperotto F. Scleroderma in children: an update. Curr Opin Pediatr. 2016;28:630–9.

40. Goel R, Danda D, Kumar S, et al. Anti-Interleukin-6 (IL-6) receptor antibody. Mol Cancer Ther. 2012;11:1623–6.
67. Turcotte LM, Correll CK, Reed RC, et al. Sustained remission of severe multicentric Castleman disease following multiagent chemotherapy and tocilizumab maintenance. Pediatr Blood Cancer. 2014;61:737–9.

68. Chantarogh S, Vilayuk S, Tim-Aroon T, et al. Clinical improvement of renal amyloidosis in a patient with systemic-onset juvenile idiopathic arthritis who received tocilizumab treatment: a case report and literature review. BMC Nephrol. 2017;18:159.

69. Okuda Y, Takasugi K. Successful use of a humanized anti-interleukin-6 receptor antibody, tocilizumab, to treat amyloid a amyloidosis complicating juvenile idiopathic arthritis. Arthritis Rheum. 2006;54:2997–3000.

70. Hakala M, Immonen K, Koopela M, et al. Good medium-term efficacy of tocilizumab in DMARD and anti-TNF-alpha therapy resistant reactive amyloidosis. Ann Rheum Dis. 2013;72:646–5.

71. Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124:188–95.

72. Frey N. Cytokine release syndrome: who is at risk and how to treat. Best Pract Res Clin Haematol. 2017;30:336–40.

73. Teachey DT, Rheingold SR, Maude SL, et al. Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood. 2013;121:5154–7.

74. Fitzgerald JC, Weiss SL, Maude SL, et al. Cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia. Crit Care Med. 2017;45:e124–e31.

75. La Torre F, Muratore M, Vitale A, et al. Canakinumab efficacy and long-term tocilizumab administration in tumor necrosis factor receptor-associated periodic syndrome (TRAPS). Rheumatol Int. 2015;35:1943–7.

76. Senniappan S, Hughes M, Shah P, et al. Pigmentary hypertrichosis and non-autoimmune insulin-dependent diabetes mellitus (PHID) syndrome is associated with severe chronic inflammation and cardiomyopathy, and represents a new monogenic autoinflammatory syndrome. J Pediatr Endocrinol Metab. 2015;28:877–82.

77. Bloom JL, Lin C, Imundo L, et al. H syndrome: 5 new cases from the United States with novel features and responses to therapy. Pediatr Rheumatol Online J. 2017;15:76.

78. Rafiq NK, Hussain K, Brogan PA. Tocilizumab for the treatment of SLC29A3 mutation Positive PHID syndrome. Pediatrics. 2017;140:e20163148.

79. Kiedel SM, Hoyles RK, Wilkinson NM. Efficacy of tocilizumab for interstitial lung disease in an undifferentiated autoinflammatory disorder partially responsive to anakinra. Rheumatology (Oxford). 2014;53:573–4.

80. Wiersinga WM. Advances in treatment of active, moderate-to-severe Graves’ ophthalmopathy. Lancet Diabetes Endocrinol. 2017;5:134–42.

81. Sy A, Eliasieh K, Silhick RZ. Clinical response to tocilizumab in severe thyroid eye disease. Ophthalmic Plast Reconstr Surg. 2017;33:e55–7.

82. Rutnaru D, Perez-Moreiras J, Sanchez-Ramon S. Anti-IL-6R therapy on Graves’ ophthalmopathy. Clin Immunol. 2013;147:120–1.

83. Perez-Moreiras J, Gomez-Reino JJ, Maneiro JR, et al. Efficacy of tocilizumab in patients with moderate to severe corticosteroid resistant Graves orbitopathy: a randomized clinical trial. Ann J Ophthalmol. 2018;195:181–90.